Adaptive Biotech And Collaborators Present New Data Demonstrating Potential Utility Of Next-Generation Sequencing Based Minimal Residual Disease (MRD) Testing As A Surrogate Endpoint For Multiple Myeloma Clinical Trials

ORLANDO, Fla.--(BUSINESS WIRE)--Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T-cell and B-cell receptors of the adaptive immune system, and collaborators from the Dana-Farber Cancer Institute and University Hospital in Toulouse, France will today present data showing that Adaptive’s NGS-based MRD assessment method (available for clinical use through Adaptive’s CLIA-certified laboratory as the clonoSEQ® Process) sensitively detects minute traces of myeloma in clinical trial patients and predicts outcomes better than flow cytometry, supporting the use of the technique as a surrogate endpoint.